Published in Antimicrob Agents Chemother on March 01, 2001
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44
Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. Antiviral Res (2009) 1.13
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother (2002) 0.87
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother (2000) 1.75
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS (1998) 1.14
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Alignment and sensitive detection of DNA by a moving interface. Science (1994) 4.18
Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet (1995) 3.81
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 3.45
Mycobacterium simiae and Mycobacterium avium-M. intracellulare mixed infection in acquired immune deficiency syndrome. J Clin Microbiol (1987) 3.01
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med (1998) 2.99
An evaluation of iridology. JAMA (1979) 2.56
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother (2008) 2.17
Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction. J Clin Microbiol (1991) 2.16
[Change in therapy target and therapy limitations in intensive care medicine. Position paper of the Ethics Section of the German Interdisciplinary Association for Intensive Care and Emergency Medicine]. Anaesthesist (2013) 2.14
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet (1997) 2.11
Hepatitis C virus and essential mixed cryoglobulinaemia. Br J Rheumatol (1993) 2.08
Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nat Genet (1999) 2.04
Decreased regional blood flow in patients with acromegaly. Clin Endocrinol (Oxf) (1998) 1.99
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 1.89
Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant (2010) 1.87
The use of ampicillin in a simplified selective medium for the isolation of fluorescent pseudomonads. J Appl Bacteriol (1974) 1.83
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Pulsed Doppler: determination of diameter, blood flow velocity, and volumic flow of brachial artery in man. Cardiovasc Res (1981) 1.76
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS (1999) 1.75
Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer (2006) 1.73
T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol (2001) 1.68
The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. Clin Infect Dis (1998) 1.67
Four multifaceted countrywide campaigns to promote hand hygiene in Belgian hospitals between 2005 and 2011: impact on compliance to hand hygiene. Euro Surveill (2012) 1.66
Concomitant infection by human herpesvirus 6, HTLV-I, and HIV-2. Lancet (1988) 1.66
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis (2005) 1.64
CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol (2000) 1.62
Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation (2000) 1.58
Young low responders protected from untoward effects of reduced ovarian response. Fertil Steril (1998) 1.57
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology (1993) 1.56
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest (2001) 1.51
The effect of estradiol depletion during the luteal phase on endometrial development. Fertil Steril (1994) 1.51
Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis (1998) 1.50
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med (2005) 1.48
Deletion of glutamate receptor-A (GluR-A) AMPA receptor subunits impairs one-trial spatial memory. Behav Neurosci (2007) 1.48
Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS (1999) 1.47
Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology (2000) 1.47
Unexpected high frequency of skeletal dysplasia in idiopathic short stature and small for gestational age patients. Eur J Endocrinol (2014) 1.46
Synthesis of a Möbius aromatic hydrocarbon. Nature (2003) 1.45
Observer variability in the diagnosis and management of the hysterosalpingogram. Fertil Steril (1997) 1.45
Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study. Clin Infect Dis (1998) 1.44
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem (1997) 1.43
Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol (1996) 1.43
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis (1995) 1.43
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.41
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups. J Immunol (2000) 1.39
A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis (1996) 1.39
Neighbourhood renewal and health: evidence from a local case study. Health Place (2001) 1.38
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37
Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med (2013) 1.37
Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol (1989) 1.35
Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet (2001) 1.34
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med (1995) 1.34
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology (1992) 1.32
Assessment of elastin and collagen contribution to aortic elasticity in conscious dogs. Am J Physiol (1991) 1.32
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother (2011) 1.32
Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother (2009) 1.31
Effects of hypertension on viscoelasticity of carotid and femoral arteries in humans. Hypertension (1995) 1.30
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol (2009) 1.30
Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med (1999) 1.30